Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer

• The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking approval for pemigatinib for cholangiocarcinoma.

• The FGFR1/2/3 inhibitor's application covers adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement.

• Pemigatinib is a tyrosine kinase inhibitor discovered by Incyte Corporation (NASDAQ: INCY) and is licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.

• The submission is based on results from abridging study showing the overall response rate (ORR) of 37%, including four complete responses (3.7%) and 36 partial responses (33.3%).

• The median duration of response (DOR) was 8.08 months, and the median progression-free survival (PFS) was 7.03 months.

• Price Action: INCY shares are down 0.69% at $80.87 on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters

• FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.